Hi, I am Maurizio Bifulco, My LiveDNA is 39.6093
 
   
  Home
 
 
 
Dr. Maurizio Bifulco
 
Highest Degree: M.D. in Medicine from Universita degli Studi di Napoli Federico II, Italy
 
Institute: Universita degli Studi di Salerno, Italy
 
Area of Interest: Biomedical Sciences
  •   Plasmatic Protein Effects
  •   Thyreotropin Hormone
  •   Cholesterol Metabolism
  •   Cellular Morphology
 
URL: http://livedna.org/39.6093
 
My SELECTED Publications
1:   Aloj, S.M., F. Beguinot, M. Bifulco and L.D. Kohn, 1988. Thyrotropin regulation of thyroid cell functions: mechanism and relationship to thyroid disease. Annali Istituto Superiore Sanita, 24: 117-128.
2:   Aquila, S., C. Guido, A. Santoro, I. Perrotta, C. Laezza, M. Bifulco and A. Sebastiano, 2010. Human sperm anatomy: Ultrastructural localization of the cannabinoid1 receptor and a potential role of anandamide in sperm survival and acrosome reaction. Anat. Rec., 293: 298-309.
CrossRef  |  
3:   Aquila, S., C. Guido, A. Santoro, P. Gazzerro and C. Laezza et al., 2010. Rimonabant (SR141716) induces metabolism and acquisition of fertilizing ability in human sperm. Br. J. Pharmacol., 159: 831-841.
CrossRef  |  
4:   Aquila, S., C. Guido, C. Laezza, A. Santoro and V. Pezzi et al., 2009. A new role of anandamide in human sperm: Focus on metabolism. J. Cell. Physiol., 221: 147-153.
CrossRef  |  
5:   Beguinot, F., L. Beguinot, D. Tramontano, C. Duilio and S. Formisano et al., 1987. Thyrotropin regulation of membrane lipid fluidity in the FRTL-5 thyroid cell line. Its relationship to cell growth and functional activity. J. Biol. Chem., 262: 1575-1582.
PubMed  |  
6:   Benavides, A., A. Napolitano, C. Bassarello, V. Carbone and P. Gazzerro et al., 2009. Oxylipins from Dracontium loretense. J. Nat. Prod., 72: 813-817.
CrossRef  |  
7:   Bifulco M. and P. Gazzerro, 2013. The critic network among scientists, the right to care and the expectations of our society: The case of a controversial stem-cell therapy in Italy. EMBO Rep., 14: 578-578.
8:   Bifulco, M. and A. Santoro, 2009. Comment on When in Rome, reform. EMBO Rep., Vol. 10. 10.1038/embor.2009.38.
CrossRef  |  
9:   Bifulco, M. and M.G. Caruso, 2007. From the gastronomic revolution to the new globesity epidemic. J. Am. Diet Assoc., 107: 2058-2560.
CrossRef  |  PubMed  |  Direct Link  |  
10:   Bifulco, M. and P. Cavallo, 2007. Thyroidology in the medieval medical school of salerno. Thyroid, 17: 39-40.
CrossRef  |  Direct Link  |  
11:   Bifulco, M. and S. Pisanti, 2009. End of the line for cannabinoid receptor 1 as an anti-obesity target? An opinion. Nat. Rev. Drug Discovery, Vol. 8. 10.1038/nrd2775-c1.
CrossRef  |  
12:   Bifulco, M. and S. Pisanti, 2013. Adiponcosis: A new term to name the obesity and cancer link. J. Clinical Endocrinol. Metabolism, 98: 4664-4665.
Direct Link  |  
13:   Bifulco, M. and V. Di Marzo, 2002. Targeting the endocannabinoid system in cancer therapy: A call for further research. Nat. Med., 8: 547-550.
CrossRef  |  PubMed  |  Direct Link  |  
14:   Bifulco, M., 2005. Role of the isoprenoid pathway in ras transforming activity, cytoskeleton organization, cell proliferation and apoptosis. Life Sci., 77: 1740-1749.
CrossRef  |  PubMed  |  Direct Link  |  
15:   Bifulco, M., 2007. Brains made in Italy: Locked or unlocked? PLOS Med. .
Direct Link  |  
16:   Bifulco, M., 2007. Possible relationship between statin use and decreased prevalence, number and volume of thyroid nodules: A new indication for these drugs? Thyroid, 17: 903-903.
CrossRef  |  PubMed  |  Direct Link  |  
17:   Bifulco, M., 2008. In memory of nino salvatore: Tenth anniversary. Thyroid, 18: 91-92.
18:   Bifulco, M., 2008. Therapeutic potential of statins in thyroid proliferative disease. Nat. Clin. Pract. Endocrinol. Metab., 4: 242-243.
CrossRef  |  PubMed  |  Direct Link  |  
19:   Bifulco, M., 2009. The endocannabinoid system: From biology to therapy. Pharmacol. Res., 60: 75-76.
20:   Bifulco, M., 2013. Risk of diabetes with statins must be monitored in each patient. BMJ., Vol. 347. (In Press). 10.1136/bmj.f4170.
CrossRef  |  
21:   Bifulco, M., A. D'Alessandro, S. Paladino, A.M. Malfitano, M. Notarnicola, M.G. Caruso and C. Laezza, 2013. N6‐isopentenyladenosine improves nuclear shape in fibroblasts from humans with progeroid syndromes by inhibiting the farnesylation of prelamin A. FEBS J., 280: 6223-6232.
CrossRef  |  
22:   Bifulco, M., A. Santoro, C. Laezza and A.M. Malfitano, 2009. Cannabinoid receptor CB1 antagonists: State of the art and challenges. Vitamins Hormones, 81: 159-189.
CrossRef  |  
23:   Bifulco, M., A.M. Malfitano and G. Marasco, 2008. Potential therapeutic role of statins in neurological disorders. Expert Rev. Neurother., 8: 827-837.
CrossRef  |  PubMed  |  
24:   Bifulco, M., A.M. Malfitano, M.C. Proto, A. Santoro, M.G. Caruso and C. Laezza, 2008. Biological and pharmacological roles of N6-Isopentenyladenosine: An emerging anticancer drug. Anticancer Agents Med. Chem., 8: 200-204.
CrossRef  |  PubMed  |  
25:   Bifulco, M., A.M. Malfitano, S. Pisanti, C. Laezza, 2008. Endocannabinoids in endocrine and related tumours. Endocr. Related Cancer, 15: 391-408.
CrossRef  |  PubMed  |  
26:   Bifulco, M., B. Perillo, M. Saji, C. Laezza, I. Tedesco, L.D. Kohn and S.M. Aloj, 1995. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in FRTL-5 cells. I. Identification and characterization of a cyclic AMP-responsive element in the rat reductase promoter. J. Biol. Chem., 270: 15231-15236.
PubMed  |  
27:   Bifulco, M., C. Grimaldi, P. Gazzerro, S. Pisanti and A. Santoro, 2007. Rimonabant: Just an antiobesity drug? Current evidence on its pleiotropic effects. Mol. Pharmacol., 71: 1445-1456.
PubMed  |  
28:   Bifulco, M., C. Laezza and A.M. Malfitano, 2007. From anecdotal evidence of cannabinoids in multiple sclerosis to emerging new therapeutical approaches. Mult. Scler., 13: 133-134.
CrossRef  |  Direct Link  |  
29:   Bifulco, M., C. Laezza and S.M. Aloj, 1999. Inhibition of farnesylation blocks growth but not differentiation in FRTL-5 thyroid cells. Biochimie, 81: 287-290.
CrossRef  |  PubMed  |  Direct Link  |  
30:   Bifulco, M., C. Laezza, G. Portella, M. Vitale, P. Orlando, L. De Petrocellis and V. Di Marzo, 2001. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J., 15: 2745-2747.
PubMed  |  
31:   Bifulco, M., C. Laezza, M. Valenti, A. Ligresti, G. Portella and V. Di Marzo, 2004. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J., 18: 1606-1608.
PubMed  |  
32:   Bifulco, M., C. Laezza, S. Pisanti and P. Gazzerro, 2006. Cannabinoids and cancer: Pros and cons of an antitumour strategy. Br. J. Pharmacol., 148: 123-135.
CrossRef  |  PubMed  |  Direct Link  |  
33:   Bifulco, M., C. Laezza, S. Stingo and J. Wolff, 2002. 2',3'-Cyclic nucleotide 3'-phosphodiesterase: A membrane-bound, microtubule-associated protein and membrane anchor for tubulin. Proc. Natl. Acad. Sci., 99: 1807-1812.
PubMed  |  
34:   Bifulco, M., C. Laezza, S.M. Aloj and C. Garbi, 1993. Mevalonate controls cytoskeleton organization and cell morphology in thyroid epithelial cells. J. Cell. Physiol., 155: 340-348.
CrossRef  |  Direct Link  |  
35:   Bifulco, M., H.A. Saroff, L.D. Kohn and S.M. Aloj, 1985. Thyrotropin interaction with high-density lipoproteins. Biochem. Biophys. Acta Lipids Lipid Metab., 835: 191-200.
CrossRef  |  PubMed  |  Direct Link  |  
36:   Bifulco, M., I.M. Spitz, H.J. Hirsh, Z. Shorer and S.M. Aloj, 1987. High-molecular-weight serum thyrotropin revisited. N. Engl. J. Med., 316: 1609-1610.
CrossRef  |  PubMed  |  Direct Link  |  
37:   Bifulco, M., M. Marasco and S. Pisanti, 2008. Dietary recommendations in the medieval medical school of salerno: A lesson from the past. Am. J. Pharm. Med., 35: 602-603.
38:   Bifulco, M., M. Santillo, I. Tedesco, R. Zarrilli, C. Laezza, and S.M. Aloj, 1990. Thyrotropin modulates low density lipoprotein binding activity in FRTL-5 thyroid cells. J. Biol. Chem., 265: 19336-19342.
PubMed  |  Direct Link  |  
39:   Bifulco, M., P. Gazzerro, C. Laezza and F. Pentimalli, 2007. Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (review). Oncol. Rep., 17: 813-816.
PubMed  |  
40:   Bonapace, J.M., R. Addeo, L. Altucci, L. Cicatiello and M. Bifulco et al., 1996. 17-Estradiol overcomes a G1 block induced by HMG-CoA reductase inhibitors and fosters cell cycle progression without inducing ERK- 1 and -2 MAP kinases activation Oncogene, 12: 753-763.
41:   Brooks, J.W., G. Pryce, T. Bisogno, S.I. Jaggar and D.J.R. Hankey et al., 2002. Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB1/CB2 receptors. Eur. J. Pharmacol., 439: 83-92.
CrossRef  |  Direct Link  |  
42:   Bucci, C., R. Seru, T. Annella, R. Vitelli, D. Lattero, M. Bifulco, P. Mondola and M. Santillo, 1998. Free fatty acids modulate LDL receptor activity in BHK-21 cells. Atherosclerosis, 137: 329-340.
PubMed  |  
43:   Caruso, M.G., M. Notarnicola, M. Bifulco, C. Laezza and V. Guerra et al., 2003. Increased farnesyltransferase activity in human colorectal cancer: Relationship with clinicopathological features and K-ras mutation. Scand. J. Gastroenterol., 38: 80-85.
PubMed  |  
44:   Caruso, M.G., P. Gazzerro, M. Notarnicola, A.M. Cisternino and V. Guerra et al., 2012. Cannabinoid type 1 receptor gene polymorphism and macronutrient intake. J. Nutrigenet. Nutrigenomics, 5: 305-313.
CrossRef  |  PubMed  |  
45:   Cavallo, P., M.C. Proto, C. Patruno, A.D. Sorbo and M. Bifulco, 2008. The first cosmetic treatise of history. A female pointof view. Int. J. Cosmet. Sci., 30: 79-86.
Direct Link  |  
46:   Ciaglia, E., S. Pisanti, P. Picardi, C. Laezza and A.M. Malfitano et al., 2013. N6-isopentenyladenosine, an endogenous isoprenoid end product, directly affects cytotoxic and regulatory functions of human NK cells through FDPS modulation. J. Leukoc Biol., 94: 1207-1219.
CrossRef  |  
47:   Corea, G., M. Iorizzi, V. Lanzotti, M. Cammareri, C. Conicella, C. Laezza and M. Bifulco, 2004. Astersedifolioside A-C, three new oleane-type saponins with antiproliferative activity. Bioorg. Med. Chem., 12: 4909-4915.
CrossRef  |  PubMed  |  Direct Link  |  
48:   Cozzolino, R., G. Cali, M. Bifulco and P. Laccetti, 2010. A metabolically stable analogue of anandamide, Met-F-AEA, inhibits human thyroid carcinoma cell lines by activation of apoptosis. Invest. New Drugs, 28: 115-123.
CrossRef  |  
49:   Cuda, G., R. Paterno, R. Ceravolo, M. Candidiota and N. Perrotti et al., 2002. Protection of human endothelial cells from oxidative stress: Role of Ras-ERK1/2 signalling. Circulation, 105: 968-974.
PubMed  |  
50:   De Lago, E., A. Ligresti, G. Ortar, E. Morera and A. Cabranes et al., 2004. In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. Eur. J. Pharmacol., 484: 249-257.
CrossRef  |  PubMed  |  Direct Link  |  
51:   De Petrocellis, L., D. Melck, A. Palmisano, T. Bisogno, C. Laezza, M. Bifulco and V. Di Marzo, 1998. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Natl. Acad. Sci., 95: 8375-8380.
52:   De Petrocellis, L., T. Bisogno, A. Ligresti, M. Bifulco, D. Melck and V. Di Marzo, 2002. Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundam. Clin. Pharmacol., 16: 297-302.
CrossRef  |  PubMed  |  Direct Link  |  
53:   Delfino, M., A. Piccirillo, M. Bifulco, A. Filla and G. Fabbrocini, 1987. Alterations in lipid and steroid metabolism in X-linked ichthyosis. Ital. Gen. Rev. Dermatol., 24: 247-250.
54:   Di Marzo, V., D. Melck, P. Orlando, T. Bisogno and O. Zagoory et al., 2001. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem. J., 358: 249-255.
PubMed  |  
55:   Di Marzo, V., M. Bifulco and L. De Petrocellis, 2000. Endocannabinoids and multiple sclerosis: A blessing from the inner bliss? Trends Pharmacol. Sci., 21: 195-197.
CrossRef  |  PubMed  |  Direct Link  |  
56:   Di Marzo, V., M. Bifulco and L. De Petrocellis, 2004. The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discovery, 3: 771-784.
CrossRef  |  Direct Link  |  
57:   Di Matola, T., F. D'Ascoli, C. Luongo, M. Bifulco, G. Rossi, G. Fenzi and M. Vitale, 2001. Lovastatin-induced apoptosis in thyroid cells: involvement of cytochrome c and lamin B. Eur. J. Endocrinol., 145: 645-650.
PubMed  |  
58:   Di Matola, T., F. Muller, G. Fenzi, G. Rossi, M. Bifulco, L.A. Marzano and M. Vitale, 2000. Serum withdrawal-induced apoptosis in thyroid cells is caused by loss of fibronectin-integrin interaction. J. Clin. Endocrinol. Metab., 85: 1188-1193.
PubMed  |  
59:   Donadelli, M., I. Dando, T. Zaniboni, C. Costanzo and E. Dalla Pozza et al., 2011. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis., Vol. 2. 10.1038/cddis.2011.36.
CrossRef  |  
60:   Eletto, D., A. Leone, M. Bifulco and M.F. Tecce, 2005. Effect of unsaturated fat intake from mediterranean diet on rat liver mRNA expression profile: Selective modulation of genes involved in lipid metabolism. Nutr. Metab. Cardiovasc. Dis., 15: 13-23.
CrossRef  |  PubMed  |  Direct Link  |  
61:   Esposito, C., M. Scrima, A. Carotenuto, A. Tedeschi and P. Rovero et al., 2008. Structures and micelle locations of the nonlipidated and lipidated C-terminal membrane anchor of 2',3'-cyclic nucleotide-3'-phosphodiesterase. Biochemistry, 47: 308-319.
CrossRef  |  PubMed  |  Direct Link  |  
62:   Esposito, I., M.C. Proto, P. Gazzerro, C. Laezza and C. Miele et al., 2008. The cannabinoid CB1 receptor antagonist Rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating phosphatidylinositol-3-kinase activity. Mol. Pharmacol., 74: 1678-1686.
Direct Link  |  
63:   Gallotta, D., P. Nigro, R. Cotugno, P. Gazzerro, M. Bifulco and M.A. Belisario, 2010. Rimonabant-induced apoptosis in leukemia cell lines: Activation of caspase-dependent and-independent pathways. Biochem. Pharmacol., 80: 370-380.
CrossRef  |  
64:   Gangemi, G., P. Gazzerro, D. Fiore, M.C. Proto and S. Butini et al., 2013. PBOX-15 induces apoptosis and improves the efficacy of oxaliplatin in human colorectal cancer cell lines. Eur. J. Pharmacol., 714: 379-387.
CrossRef  |  PubMed  |  
65:   Garbi, C., C. Zurzolo, M. Bifulco and L. Nitsch, 1988. Synthesis of extracellular matrix glycoproteins by a differentiated thyroid epithelial cell line. J. Cell Physiol., 135: 39-46.
PubMed  |  
66:   Gazzerro P. and M. Bifulco, 2013. Statins and cancer in gastroenterology: New insight? Gastroenterology, 144: 1572-1573.
CrossRef  |  
67:   Gazzerro, P., A.M. Malfitano, M.C. Proto, A. Santoro and S. Pisanti et al., 2010. Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin. Oncol. Rep., 23: 171-175.
CrossRef  |  
68:   Gazzerro, P., E. Ciaglia and M. Bifulco, 2013. Statins and cancer‐related mortality: An open question. Basic Clinical Pharmacol. Toxicol., 113: 73-74.
CrossRef  |  
69:   Gazzerro, P., M.C. Proto, G. Gangemi, A.M. Malfitano and E. Ciaglia et al., 2012. Pharmacological actions of statins: A critical appraisal in the management of cancer. Pharmacol. Rev., 64: 102-146.
CrossRef  |  
70:   Gazzerro, P., M.G. Caruso, M. Notarnicola, G. Misciagna, V. Guerra, C. Laezza and M. Bifulco, 2007. Association between cannabinoid type-1 receptor polymorphism and body mass index in a Southern Italian population. Int. J. Obes., 31: 908-912.
CrossRef  |  PubMed  |  Direct Link  |  
71:   Grieco, D., Z.H. Beg, A. Romano, M. Bifulco and S.M. Aloj, 1990. Cell cycle progression and 3-hydroxy-3-methylglutaryl coenzyme A reductase are regulated by thyrotropin in FRTL-5 rat thyroid cells. J. Biol. Chem., 265: 19343-19350.
PubMed  |  
72:   Grimaldi, C. and M. Bifulco, 2007. Anandamide, an endogenous ligand of cannabinoid receptors, inhibits human breast cancer cell proliferation through a lipid rafts mediated mechanism. Pharmacologyonline, 1: 1-45.
73:   Grimaldi, C., S. Pisanti, C. Laezza, A.M. Malfitano and A. Santoro et al., 2006. Anandamide inhibits adhesion and migration of breast cancer cells. Exp. Cell Res., 312: 363-373.
CrossRef  |  PubMed  |  Direct Link  |  
74:   Guerra, A., P. Zeppa, M. Bifulco and M. Vitale, 2013. Concomitant BRAFV600E mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma. Thyroid, (In Press). .
PubMed  |  Direct Link  |  
75:   Harrison, S., L. De Petrocellis, M. Trevisani, F. Benvenuti, M. Bifulco, P. Geppetti and V. Di Marzo, 2003. Capsaicin-like effects of N-arachidonoyl-dopamine in the isolated guinea pig bronchi and urinary bladder. Eur. J. Pharmacol., 475: 107-114.
CrossRef  |  PubMed  |  Direct Link  |  
76:   Laezza, C., A. D'Alessandro, S. Paladino, A. Maria Malfitano and M. Chiara Proto et al., 2012. Anandamide inhibits the Wnt/β-catenin signalling pathway in human breast cancer MDA MB 231 cells. Eur. J. Cancer, 48: 3112-3122.
CrossRef  |  
77:   Laezza, C., A. Migliaro, R. Cerbone, I. Tedesco, M. Santillo, C. Garbi and M. Bifulco, 1997. N6-Isopentenyladenosine affects cAMP-dependent microfilament organization in FRTL-5 thyroid cells. Exp. Cell Res., 234: 178-182.
CrossRef  |  Direct Link  |  
78:   Laezza, C., A. d'Alessandro, A.M. Malfitano and M. Bifulco, 2013. Anandamide inhibits the Wnt/β-catenin signalling pathway in human breast cancer MDA MB 231 cells. Eur. J. Cancer, 49: 2066-2067.
CrossRef  |  PubMed  |  
79:   Laezza, C., A.M. Malfitano, M.C. Proto, I. Esposito and P. Gazzerro et al., 2010. Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cells. Endocr. Related Cancer, 17: 495-503.
CrossRef  |  
80:   Laezza, C., A.M. Malfitano, T. Di Matola, P. Ricchi and M. Bifulco, 2010. Involvement of Akt/NF‐κB pathway in N6‐isopentenyladenosine‐induced apoptosis in human breast cancer cells. Mol. Carcinog., 49: 892-901.
CrossRef  |  
81:   Laezza, C., C. Bucci, M. Santillo, C.B. Bruni and M. Bifulco, 1998. Control of Rab5 and Rab7 expression by the isoprenoid pathway. Biochem. Biophys. Res. Commun., 248: 469-472.
CrossRef  |  PubMed  |  Direct Link  |  
82:   Laezza, C., G. Mazziotti, L. Fiorentino, P. Gazzerro and G. Portella et al., 2006. HMG-CoA reductase inhibitors inhibit rat propylthiouracil-induced goiter by modulating the ras-MAPK pathway. J. Mol. Med., 84: 967-973.
CrossRef  |  PubMed  |  Direct Link  |  
83:   Laezza, C., J. Wolff and M. Bifulco, 1997. Identification of a 48-kDa prenylated protein that associates with microtubules as 2',3'-cyclic nucleotide 3'-phosphodiesterase in FRTL-5 cells. FEBS Lett., 413: 260-264.
CrossRef  |  PubMed  |  Direct Link  |  
84:   Laezza, C., L. Fiorentino, S. Pisanti, P. Gazzerro and M. Caraglia et al., 2008. Lovastatin induces apoptosis of k-ras-transformed thyroid cells via inhibition of ras farnesylation and by modulating redox state. J. Mol. Med., 86: 1341-1351.
CrossRef  |  PubMed  |  Direct Link  |  
85:   Laezza, C., M. Notarnicola, M.G. Caruso, C. Messa and M. Macchia et al., 2006. N6-isopentenyladenosine arrests tumor cell proliferation by inhibiting farnesyl diphosphate synthase and protein prenylation. FASEB J., 20: 412-418.
PubMed  |  
86:   Laezza, C., M.G. Caruso, T. Gentile, M. Notarnicola and A.M. Malfitano et al., 2009. N6-isopentenyladenosine inhibits cell proliferation and induces apoptosis in a human colon cancer cell line DLD1. Int. J. Cancer, 124: 1322-1329.
CrossRef  |  PubMed  |  Direct Link  |  
87:   Laezza, C., S. Pisanti, A.M. Malfitano and M. Bifulco, 2008. The anandamide analog, Met-F-AEA, controls human breast cancer cell migration via the RHOA/RHO kinase signaling pathway. Endocr. Related Cancer, 15: 965-974.
CrossRef  |  PubMed  |  
88:   Laezza, C., S. Pisanti, E. Crescenzi and M. Bifulco, 2006. Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells. FEBS Lett., 580: 6076-6082.
CrossRef  |  PubMed  |  Direct Link  |  
89:   Laezza, C., V. Di Marzo and M. Bifulco, 1998. V-K-ras leads to preferential farnesylation of p21ras in FRTL-5 cells: Multiple interference with the isoprenoid pathway. Proc. Natl. Acad. Sci., 95: 13646-13651.
PubMed  |  
90:   Libertini, S., I. Iacuzzo, A, Ferraro, M. Vitale, M. Bifulco, A. Fusco and G. Portella, 2007. Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells. Endocrinology, 148: 5186-5194.
PubMed  |  
91:   Ligresti, A., T. Bisogno, I. Matias, L. De Petrocellis and M.G. Cascio et al., 2003. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology, 125: 677-687.
CrossRef  |  PubMed  |  Direct Link  |  
92:   Linsalata, M., M. Notarnicola, V. Tutino, M. Bifulco and A. Santoro et al., 2010. Effects of anandamide on polyamine levels and cell growth in human colon cancer cells. Anticancer Res., 30: 2583-2589.
Direct Link  |  
93:   Malfitano, A.M., C. Laezza, A. D'Alessandro, C. Procaccini and G. Saccomanni et al., 2013. Effects on immune cells of a new 1, 8-naphthyridin-2-one derivative and its analogues as selective CB2 agonists: Implications in multiple sclerosis. PloS One, Vol. 8. 10.1371/journal.pone.0062511.
CrossRef  |  
94:   Malfitano, A.M., C. Laezza, G. Saccomanni, T. Tuccinardi and C. Manera et al., 2013. Immune-modulation and properties of absorption and blood brain barrier permeability of 1, 8-naphthyridine derivatives. J. Neuroimmune Pharmacol., 8: 1077-1086.
CrossRef  |  
95:   Malfitano, A.M., C. Laezza, M. Galgani, G. Matarese, A. D'Alessandro, P. Gazzerro and M. Bifulco, 2012. The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice. Pharmacol. Res., 65: 365-371.
CrossRef  |  
96:   Malfitano, A.M., C. Laezza, S. Pisanti, P. Gazzerro and M. Bifulco, 2008. Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells. Br. J. Pharmacol., 153: 1003-1010.
CrossRef  |  PubMed  |  Direct Link  |  
97:   Malfitano, A.M., E. Ciaglia, G. Gangemi, P. Gazzerro, C. Laezza and M. Bifulco, 2011. Update on the endocannabinoid system as an anticancer target. Expert Opin. Ther. Targets, 15: 297-308.
CrossRef  |  
98:   Malfitano, A.M., G. Matarese and M. Bifulco, 2005. From cannabis to endocannabinoids in multiple sclerosis: A paradigm of central nervous system autoimmune diseases. Curr. Drug Targets, 4: 667-675.
PubMed  |  
99:   Malfitano, A.M., G. Matarese, S. Pisanti, C. Grimaldi and C. Laezza et al., 2006. Arvanil inhibits T lymphocyte activation and ameliorates the course and progression of autoimmune encephalomyelitis. J. Neuroimmunol., 171: 110-119.
CrossRef  |  
100:   Malfitano, A.M., G.A. Toruner, P. Gazzerro, C. Laezza and S. Husain et al., 2007. Arvanil and anandamide up-regulate CD36 expression in human peripheral blood mononuclear cells. Immunol. Lett., 109: 145-154.
CrossRef  |  PubMed  |  Direct Link  |  
101:   Malfitano, A.M., M.C. Proto and M. Bifulco, 2008. Cannabinoids in the management of spasticity associated with multiple sclerosis. Neuropsychiatr Dis. Treat, 4: 847-853.
PubMed  |  
102:   Malfitano, A.M., R. Cahill, P. Mitchell, G. Frankel and G. Dougan et al., 2006. Helicobacter pylori has stimulatory effects on naive T cells. Helicobacter, 11: 21-30.
CrossRef  |  PubMed  |  Direct Link  |  
103:   Malfitano, A.M., S. Sosa, C. Laezza, M. De Bortoli, A. Tubaro and M. Bifulco, 2011. Rimonabant reduces keratinocyte viability by induction of apoptosis and exerts topical anti‐inflammatory activity in mice. Br. J. Pharmacol., 162: 84-93.
CrossRef  |  
104:   Manera, C., G. Saccomanni, A.M. Malfitano, S. Bertini and F. Castelli et al., 2012. Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: An investigation of the 1, 8-naphthyridin-2 (1 H)-one scaffold. Eur. J. Med. Chem., 52: 284-294.
CrossRef  |  
105:   Marra, M., A. Lombardi, E. Agostinelli, G. Giuberti and S. Zappavigna et al., 2008. Bovine serum amine oxidase and spm potentiate docetaxel and interferon-alpha effects in inducing apoptosis on human cancer cells through the generation of oxidative stress. Biochim. Biophys. Acta Mol. Cell Res., 1783: 2269-2278.
CrossRef  |  PubMed  |  Direct Link  |  
106:   Melck, D., L. De Petrocellis, P. Orlando, T. Bisogno, C. Laezza, M. Bifulco and V. Di Marzo, 2000. Suppression of trk and prolactin receptor levels by endocannabinnoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology, 141: 118-126.
107:   Melck, D., T. Bisogno, L. De Petrocellis, H-H. Chuang, D. Julius, M. Bifulco and V. Di Marzo, 1999. Unsaturated long chain N-Acyl-Vanillyl-Amides (N-AVAMs).Vanilloid receptor ligands that inhibit anandamide facilitated transport and bind to CB1cannabinoid receptors. Biochem. Biophys. Res. Commun., 262: 275-284.
CrossRef  |  Direct Link  |  
108:   Messa, C., M. Notarnicola, F. Russo, A. Cavallini and V. Pallottini et al., 2005. Estrogenic regulation of cholesterol biosynthesis and cell growth in DLD-1 human colon cancer cells. Scand. J. Gastroenterol., 40: 1454-1461.
CrossRef  |  PubMed  |  Direct Link  |  
109:   Milone, A., M. Delfino, A. Piccirillo, G.M.P. Illiano, S.M. Aloj and M. Bifulco, 1991. Increased levels of DHEAS in serum of X-linked ichthyosis patients. J. Inherit. Metab. Dis., 14: 96-104.
PubMed  |  
110:   Minutolo, F., M.G. Cascio, I. Carboni, T. Bisogno and G. Prota et al., 2007. Metabolically labile cannabinoid esters: A soft drug approach for the development of cannabinoid-based therapeutic drugs. Bioorg. Med. Chem. Lett., 17: 4878-4881.
CrossRef  |  PubMed  |  Direct Link  |  
111:   Mondola, P., M. Bifulco, R. Seru, T. Annella, M.C. Ciriolo and M. Santillo, 2000. Presence of CuZn Superoxide Dismutase in human serum lipoproteins. FEBS Lett., 467: 57-60.
CrossRef  |  PubMed  |  Direct Link  |  
112:   Mondola, P., M. Santillo, F. Santangelo, A. Belfiore, P. Gambardella and M. Bifulco, 1992. Effects of a new calf thymus protein on 3-hydroxy-3-methylglutaryl-CoA reductase activity in rat (Rattus bubalus) hepatocyte cells (BRL-3A). Comp. Biochem. Physiol. B Comp. Biochem., 103: 431-434.
CrossRef  |  Direct Link  |  
113:   Mondola, P., M. Santillo, F. Santangelo, C. Caporale, A. Belfiore and M. Bifulco, 1989. Purification and characterization of a calf thymus protein active on lipid metabolism. Int. J. Biochem., 21: 1009-1014.
CrossRef  |  PubMed  |  Direct Link  |  
114:   Mondola, P., M. Santillo, I. Tedesco, F. Santangelo, A. Belfiore and M. Bifulco, 1989. Thymus fraction (FIII) effect on cholesterol metabolism: modulation of the low density lipoprotein receptor pathway. Int. J. Biochem., 21: 627-630.
115:   Mondola, P., R. Seru, M. Santillo, S. Damiano and M. Bifulco et al., 2002. Effect of Cu,Zn superoxide dismutase on cholesterol metabolism in human hepatocarcinoma (HepG2) cells. Biochem. Biophys. Res. Commun., 295: 603-609.
PubMed  |  
116:   Monteleone, P., M. Bifulco, C. Di Filippo, P. Gazzerro and B. Canestrelli et al., 2009. Association of CNR1 and FAAH endocannabinoid gene polymorphisms with anorexia nervosa and bulimia nervosa: Evidence for synergistic effects. Genes Brain Behav., 8: 728-732.
CrossRef  |  
117:   Monteleone, P., M. Bifulco, G. Maina, A. Tortorella and P. Gazzerro et al., 2010. Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. Pharmacol. Res., 61: 400-404.
CrossRef  |  
118:   Notarnicola, M., C. Messa, A. Cavallini, M. Bifulco and M.F. Tecce et al., 2004. Higher farnesyl diphosphate synthase activity in human colorectal cancer inhibition of cellular apoptosis. Oncology, 67: 351-358.
PubMed  |  
119:   Notarnicola, M., C. Messa, A. Orlando, M. Bifulco, C. Laezza, P. Gazzerro and M.G. Caruso, 2008. Estrogenic induction of cannabinoid CB1 receptor in human colon cancer cell lines. Scand. J. Gastroenterol., 43: 66-72.
PubMed  |  
120:   Notarnicola, M., D.F. Altomare, M. Calvani, A. Orlando, M. Bifulco, B. D'Attoma and M.G. Caruso, 2007. Fatty acid synthase hyperactivation in human colorectal cancer: Relationship with tumor side and sex. Oncology, 71: 327-332.
PubMed  |  
121:   Notarnicola, M., S. Pisanti, V. Tutino, D. Bocale and M.T. Rotelli et al., 2011. Effects of olive oil polyphenols on fatty acid synthase gene expression and activity in human colorectal cancer cells. Genes Nutr., 6: 63-69.
CrossRef  |  
122:   Paolillo, M., A. Feliciello, A. Porcellini, C. Garbi and M. Bifulco et al., 1999. The type and the localization of cAMP-dependent protein kinase regulate transmission of cAMP signals to the nucleus in cortical and cerebellar granule cells. J. Biol. Chem., 274: 6546-6552.
CrossRef  |  PubMed  |  Direct Link  |  
123:   Perillo, B., I. Tedesco, C. Laezza, M. Santillo, A. Romano, S.M. Aloj and M. Bifulco, 1995. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in FRTL-5 cells. II. Down-regulation by v-K-ras oncogene. J. Biol. Chem., 270: 15237-15241.
PubMed  |  
124:   Pisanti, S. and M. Bifulco, 2009. Endocannabinoid system modulation in cancer biology and therapy. Pharmacol. Res., 60: 107-116.
CrossRef  |  
125:   Pisanti, S., A.M. Malfitano, C. Grimaldi, A. Santoro, P. Gazzerro, C. Laezza and M. Bifulco, 2009. Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. Best Pract. Res. Clin. Endocrinol. Metab., 23: 117-131.
CrossRef  |  
126:   Pisanti, S., C. Borselli, P. Gazzerro, C. Laezza and M. Bifulco, 2006. Antiangiogenic activity of the endocannabinoid anandamide: Correlation to its tumor-suppressor efficacy. J. Cell. Physiol., 211: 495-503.
CrossRef  |  PubMed  |  Direct Link  |  
127:   Pisanti, S., P. Picardi, A. D'Alessandro, C. Laezza and M. Bifulco, 2013. The endocannabinoid signaling system in cancer. Trends Pharmacol. Sci., 34: 273-282.
CrossRef  |  
128:   Pisanti, S., P. Picardi, L. Prota, M.C. Proto and C. Laezza et al., 2011. Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis. Blood, 117: 5541-5550.
CrossRef  |  
129:   Portella, G., C. Laezza, P. Laccetti, L. De Petrocellis, V. Di Marzo and M. Bifulco, 2003. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: Actions on signals involved in angiogenesis and metastasis. FASEB J., 17: 1771-1773.
PubMed  |  
130:   Prota, L., A. Santoro, M. Bifulco, R.P. Aquino, T. Mencherini and P. Russo, 2011. Leucine enhances aerosol performance of Naringin dry powder and its activity on cystic fibrosis airway epithelial cells. Int. J. Pharmaceutics, 412: 8-19.
CrossRef  |  
131:   Proto, M.C., P. Gazzerro, L. Di Croce, A. Santoro and A.M. Malfitano et al., 2012. Interaction of endocannabinoid system and steroid hormones in the control of colon cancer cell growth. J. Cell. Physiol., 227: 250-258.
CrossRef  |  
132:   Salzano, M., M.R. Rusciano, E. Russo, M. Bifulco, L. Postiglione and M. Vitale, 2012. Calcium/calmodulin-dependent protein kinase II (CaMKII) phosphorylates Raf-1 at serine 338 and mediates Ras-stimulated Raf-1 activation. Cell Cycle, 11: 2100-2106.
Direct Link  |  
133:   Santillo, M., A. Migliaro, P. Mondola, C. Laezza and S. Damiano et al., 1999. Dietary and hypothyroid hypercholesterolemia induces hepatic apolipoprotein E expression in the rat: Direct role of cholesterol. FEBS Lett., 463: 83-86.
CrossRef  |  PubMed  |  Direct Link  |  
134:   Santillo, M., P. Mondola, A. Gioielli, R. Seru and S. Iossa et al., 1996. Inhibitors of ras farnesylation revert the increased resistance to oxidative stress in K-ras transformed NIH 3T3 Cells. Biochem. Biophys. Res. Commun., 229: 739-745.
CrossRef  |  Direct Link  |  
135:   Santillo, M., P. Mondola, A. Milone, A. Gioielli and M. Bifulco, 1996. Ascorbate administration to normal and cholesterol-fed rats inhibits in vitro TBARS formation in serum and liver homogenates. Life Sci., 58: 1104-1108.
CrossRef  |  Direct Link  |  
136:   Santillo, M., P. Mondola, F. Santangelo, A. Belfiore and I. Tedesco et al., 1992. Characterization of the Low density lipoprotein receptor activity in buffalo rat liver (BRL-3A) cells. Comp. Biochem. Physiol. B Comp. Biochem., 101: 489-494.
CrossRef  |  PubMed  |  Direct Link  |  
137:   Santoro, A., G. Bianco, P. Picerno, R.P. Aquino and G. Autore et al., 2008. Verminoside- and verbascoside-induced genotoxicity on human lymphocytes: Involvement of PARP-1 and p53 proteins. Toxicol. Lett., 178: 71-76.
CrossRef  |  PubMed  |  Direct Link  |  
138:   Santoro, A., P. Gazzerro, A.M. Malfitano, S. Pisanti, C. Laezza and M. Bifulco, 2008. Reply to the letter to the editor Long-term cannabinoid receptor (CB1) blockade in obesity: Implications for the development of colorectal cancer. Int. J. Cancer, 123: 243-244.
CrossRef  |  PubMed  |  Direct Link  |  
139:   Santoro, A., S. Pisanti, C. Grimaldi, A.A. Izzo and F. Borrelli et al., 2009. Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon. Int. J. Cancer, 125: 996-1003.
CrossRef  |  
140:   Sarnataro, D., C. Grimaldi, S. Pisanti, P. Gazzerro, C. Laezza, C. Zurzolo and M. Bifulco, 2005. Plasma membrane and lysosomal localization of CB1 cannabinoid receptor are dependent on lipid rafts and regulated by anandamide in human breast cancer cells. FEBS Lett., 579: 6343-6349.
CrossRef  |  PubMed  |  Direct Link  |  
141:   Sarnataro, D., S. Pisanti, A. Santoro, P. Gazzerro, A.M. Malfitano, C. Laezza and M. Bifulco, 2006. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol. Pharmacol., 70: 1298-1306.
PubMed  |  
142:   Scrima, M., S. Di Marino, M. Grimaldi, A. Mastrogiacomo, E. Novellino, M. Bifulco and A.M. D'Ursi, 2010. Binding of the hemopressin peptide to the cannabinoid CB1 receptor: Structural insights. Biochemistry, 49: 10449-10457.
CrossRef  |  
143:   Stingo, S., M. Masullo, E. Polverini, C. Laezza and I. Ruggiero et al., 2007. The N-Terminal domain of 2',3'-cyclic nucleotide 3'-phosphodiesterase harbors a GTP/ATP binding site. Chem. Biol. Drug Des., 70: 502-510.
CrossRef  |  PubMed  |  Direct Link  |  
144:   Vitale, M. and M. Bifulco, 2009. Thyroid cellular models: A warning concerning their application. Thyroid, 19: 1021-1022.
CrossRef  |  
145:   Vitale, M., T. Di Matola, G. Rossi, C. Laezza, G. Fenzi and M. Bifulco, 1999. Prenyltransferase-inhibitors induce apoptosis in proliferating thyroid cells through a p53- independent, CRMA-sensitive and caspase-3-like protease dependent mechanism. Endocrinology, 140: 698-704.
146:   Vitale, M., T. Di Matola, M. Bifulco, A. Casamassima, G. Fenzi and G. Rossi, 1999. Apoptosis induced by denied adhesion to extracellular matrix (anoikis) in thyroid epithelial cells is p53 dependent but fails to correlate with modulation of p53 expression. FEBS Lett., 462: 57-60.
CrossRef  |  PubMed  |  Direct Link  |  
147:   Vitelli, R.,M. Santillo, D. Lattero, M. Chiariello, M. Bifulco, C.B. Bruni and C. Bucci, 1997. Role of the small GTP-ase Rab7 in the late endocytic pathway. J. Biol. Chem., 272: 4391-4397.